Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom

Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.

After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.

You May Also Be Interested In

• Regenxbio shares jump after FDA agrees to reverse drug rejection
• Bending Spoons valuation up to $19 Billion in U.S. IPO - Reuters
• Trump praises IBM CEO